24 results
8-K
EX-99.2
APRE
Aprea Therapeutics Inc
10 Apr 24
IND for APR-1051 has been cleared; details on planned Phase 1 first in human trial (ACESOT-1051) presented
4:15pm
and WEE1 inhibitors are integral to stopping DDR and are emerging targets for cancer cell death Builds on scientific innovation led by Aprea founder and key
8-K
EX-99.2
APRE
Aprea Therapeutics Inc
26 Mar 24
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
8:15am
on scientific innovation led by Aprea founder and key personnel1 1 Gilad et al, (2010) Cancer Res. Healthy cell Pathway A Pathway B Active cancer cell
8-K
EX-99.1
APRE
Aprea Therapeutics Inc
6 Feb 24
Other Events
5:01pm
inhibitors are integral to stopping DDR and are emerging targets for cancer cell death Builds on scientific innovation led by Aprea founder and key
8-K
EX-99.2
APRE
Aprea Therapeutics Inc
4 Jan 24
Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024
4:16pm
inhibitors are integral to stopping DDR and are emerging targets for cancer cell death Builds on scientific innovation led by Aprea founder and key
10-K
q7fw0ibiha
27 Mar 20
Annual report
4:16pm
10-Q
d0mb1gu r3c
14 Nov 19
Quarterly report
4:25pm
424B4
hda63wofu00rmdhfr
4 Oct 19
Prospectus supplement with pricing info
12:00am